Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.

Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, Sawada Y, Saikawa S, Kitagawa K, Takaya H, Kawaratani H, Kitade M, Moriya K, Noguchi R, Akahane T, Mitoro A, Yoshiji H.

Int J Mol Sci. 2020 Mar 21;21(6). pii: E2164. doi: 10.3390/ijms21062164.

2.

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.

Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

Antibiotics (Basel). 2020 Mar 29;9(4). pii: E145. doi: 10.3390/antibiotics9040145.

3.

A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn's disease.

Bamba S, Sakemi R, Fujii T, Takeda T, Fujioka S, Takenaka K, Kitamoto H, Umezawa S, Sakuraba H, Inokuchi T, Fukata N, Mizuno S, Yamashita M, Shinzaki S, Tanaka H, Takedatsu H, Ozaki R, Moriya K, Ishii M, Kinjo T, Ozeki K, Ooi M, Hayashi R, Kakimoto K, Shimodate Y, Kitamura K, Yamada A, Sonoda A, Nishida Y, Yoshioka K, Ashizuka S, Takahashi F, Shimokawa T, Kobayashi T, Andoh A, Hibi T.

J Gastroenterol. 2020 Jan 27. doi: 10.1007/s00535-020-01670-2. [Epub ahead of print]

PMID:
31989252
4.

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients.

Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, Saikawa S, Sato S, Kawaratani H, Moriya K, Akahane T, Yoshiji H.

World J Gastrointest Oncol. 2019 Oct 15;11(10):887-897. doi: 10.4251/wjgo.v11.i10.887.

5.

Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.

Tsuji Y, Kawaratani H, Ishida K, Kaya D, Kubo T, Fujinaga Y, Sawada Y, Takaya H, Shimozato N, Kaji K, Namisaki T, Moriya K, Akahane T, Yoshiji H.

Dig Dis. 2019 Oct 25:1-6. doi: 10.1159/000504044. [Epub ahead of print]

PMID:
31655803
6.

Performance of laboratory tests for detection for Clostridioides difficile: A multicenter prospective study in Japan.

Senoh M, Kato H, Honda H, Fukuda T, Tagashira Y, Horiuchi H, Chiba H, Suzuki D, Hosokawa N, Kitazono H, Norisue Y, Kume H, Mori N, Morikawa H, Kashiwagura S, Higuchi A, Kato H, Nakamura M, Ishiguro S, Morita S, Ishikawa H, Watanabe T, Kojima K, Yokomaku I, Bando T, Toimoto K, Moriya K, Kasahara K, Kitada S, Ogawa J, Saito H, Tominaga H, Shimizu Y, Masumoto F, Tadera K, Yoshida J, Kikuchi T, Yoshikawa I, Watanabe T, Honda M, Yokote K, Toyokawa T, Miyazato H, Nakama M, Mahe C, Reske K, Olsen MA, Dubberke ER.

Anaerobe. 2019 Dec;60:102107. doi: 10.1016/j.anaerobe.2019.102107. Epub 2019 Oct 21.

PMID:
31647977
7.

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.

Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H.

BMC Gastroenterol. 2019 Oct 21;19(1):167. doi: 10.1186/s12876-019-1082-1.

8.

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.

Kaya D, Kaji K, Tsuji Y, Yamashita S, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.

Cells. 2019 Sep 26;8(10). pii: E1153. doi: 10.3390/cells8101153.

9.

Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study.

Nakanishi K, Namisaki T, Mashitani T, Kaji K, Ozaki K, Saikawa S, Sato S, Inoue T, Sawada Y, Kitagawa K, Takaya H, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H.

Nutrients. 2019 Sep 7;11(9). pii: E2140. doi: 10.3390/nu11092140.

10.

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.

Moriya K, Namisaki T, Sato S, Furukawa M, Douhara A, Kawaratani H, Kaji K, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Yoshiji H.

Clin Mol Hepatol. 2019 Dec;25(4):381-389. doi: 10.3350/cmh.2019.0037. Epub 2019 Aug 13.

11.

Effect of furosemide on muscle cramps in patients with liver cirrhosis.

Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Takaya H, Kaji K, Shimozato N, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

J Gastroenterol Hepatol. 2020 Jan;35(1):76-81. doi: 10.1111/jgh.14820. Epub 2019 Aug 16.

PMID:
31385352
12.

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.

Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H.

Hepatol Res. 2019 Oct;49(10):1147-1161. doi: 10.1111/hepr.13385. Epub 2019 Jul 15.

PMID:
31177586
13.

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.

Nakanishi K, Kaji K, Kitade M, Kubo T, Furukawa M, Saikawa S, Shimozato N, Sato S, Seki K, Kawaratani H, Moriya K, Namisaki T, Yoshiji H.

Int J Mol Sci. 2019 Jun 3;20(11). pii: E2724. doi: 10.3390/ijms20112724.

14.

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.

Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H.

World J Gastrointest Oncol. 2019 May 15;11(5):424-435. doi: 10.4251/wjgo.v11.i5.424.

15.

Identification of clinical risk factors for histological progression of primary biliary cholangitis.

Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14.

PMID:
31021038
16.

Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model.

Kitade M, Kaji K, Nishimura N, Seki K, Nakanishi K, Tsuji Y, Sato S, Saikawa S, Takaya H, Kawaratani H, Namisaki T, Moriya K, Mitoro A, Yoshiji H.

Hepatol Res. 2019 Sep;49(9):1034-1045. doi: 10.1111/hepr.13351. Epub 2019 May 29.

PMID:
30989766
17.

Clostridioides (Clostridium) difficile infection burden in Japan: A multicenter prospective study.

Kato H, Senoh M, Honda H, Fukuda T, Tagashira Y, Horiuchi H, Chiba H, Suzuki D, Hosokawa N, Kitazono H, Norisue Y, Kume H, Mori N, Morikawa H, Kashiwagura S, Higuchi A, Kato H, Nakamura M, Ishiguro S, Morita S, Ishikawa H, Watanabe T, Kojima K, Yokomaku I, Bando T, Toimoto K, Moriya K, Kasahara K, Kitada S, Ogawa J, Saito H, Tominaga H, Shimizu Y, Masumoto F, Tadera K, Yoshida J, Kikuchi T, Yoshikawa I, Watanabe T, Honda M, Yokote K, Toyokawa T, Miyazato H, Nakama M, Mahe C, Reske K, Olsen MA, Dubberke ER.

Anaerobe. 2019 Dec;60:102011. doi: 10.1016/j.anaerobe.2019.03.007. Epub 2019 Mar 12.

PMID:
30872073
18.

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.

Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.

Clin Mol Hepatol. 2019 Mar;25(1):65-73. doi: 10.3350/cmh.2018.0070. Epub 2019 Feb 25.

19.

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.

Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Kawaratani H, Moriya K, Namisaki T, Mitoro A, Yoshiji H.

BMC Cancer. 2018 Nov 26;18(1):1164. doi: 10.1186/s12885-018-5099-6.

20.

von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.

Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H.

United European Gastroenterol J. 2018 Nov;6(9):1401-1409. doi: 10.1177/2050640618779660. Epub 2018 May 25.

Supplemental Content

Loading ...
Support Center